Evaluation of the Blood Levels of the Drug (Lixisenatide), the Plasma Glucose Levels and Safety in Paediatric and Adult Patients With Type 2 Diabetes

The duration of the study for each patient is planned between 4 and 7 weeks including a
screening period (25 to 30 days), 3 treatment periods 1-7 days apart, each period lasting
only one day (Day 1) and an end-of-study visit between 1 to 7 days after the last dose
administration.

Inclusion criteria :

- Male or female patients with type 2 diabetes mellitus, as defined by WHO (fasting
plasma glucose ≥ 7 mmol/L (126mg/dL) or 2 hours postprandial plasma glucose ≥ 11.1
mmol/L (200 mg/dL)), diagnosed for at least 1 year (adults) and at least 3 months for
paediatric population at the time of screening visit, with or without metformin
(stable dose ± 10 % for at least 4 weeks prior to randomization)

- HbA1c ≥ 7% and ≤ 10% at screening

- Age eligibility for paediatric population: ≥ 10 years and <18 years with at least 3
patients below 15 years and no more than 3 patients aged between 16 and 18 years; Age
eligibility for adults: ≥ 18 and ≤ 65 years

- For paediatric population:body weight >50kg, BMI >85th percentile for age and gender
and BMI ≤ 50 kg/m²

- For adults: BMI > 25 kg/m2 and ≤ 37 kg/m2

Exclusion criteria:

- If female, pregnancy (defined as positive serum pregnancy test), breast-feeding

- Diabetes other than type 2 diabetes

- Positive test for insulinoma associated protein (IA2) and glutamic acid decarboxylase
(GAD) autoantibodies

- Use of other oral or injectable antidiabetic or hypoglycemic agents other than
metformin (e.g., alpha glucosidase inhibitor, exenatide, DPP-IV inhibitors, insulin
etc.) within 3 months prior to the time of screening

- Allergic reaction to any GLP-1 agonist in the past (e.g. exenatide, liraglutide) or
to metacresol

- History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy,
stomach/gastric surgery, inflammatory bowel disease

- Personal or family history of medullary thyroid cancer (MTC) or genetic conditions
that predispose to MTC (e.g., multiple endocrine neoplasia syndromes)

The above information is not intended to contain all considerations relevant to a
patient's potential participation in a clinical trial.